As of 2:52:40 PM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -0.59 | -0.56 | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.38 | -0.4 | -0.26 | -0.25 |
| EPS Actual | -0.59 | -0.56 | -0.35 | -0.12 |
| Difference | -0.21 | -0.16 | -0.09 | 0.13 |
| Surprise % | -56.29% | -38.84% | -33.00% | 51.81% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | -- | -- |
| Up Last 30 Days | 1 | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CARA | -- | -- | -- | -- |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Downgrade | Canaccord Genuity: Buy to Hold | 6/13/2024 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 6/13/2024 |
| Downgrade | Needham: Buy to Hold | 6/13/2024 |
| Reiterates | Needham: Buy to Buy | 5/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
| Reiterates | Needham: Buy to Buy | 5/14/2024 |
Related Tickers
APTO Aptose Biosciences Inc.
0.2366
-1.83%
COEP Coeptis Therapeutics Holdings, Inc.
0.1599
-12.24%
REVB Revelation Biosciences, Inc.
0.3969
+10.85%
CDT Conduit Pharmaceuticals Inc.
0.0760
+26.59%
SLGL Sol-Gel Technologies Ltd.
1.0600
-5.36%
VIRX Viracta Therapeutics, Inc.
0.1595
-0.31%
MTEM Molecular Templates, Inc.
0.0461
+9.76%
LYRA Lyra Therapeutics, Inc.
0.2128
+11.71%
PTIX Protagenic Therapeutics, Inc.
0.5194
-6.41%
VINC Vincerx Pharma, Inc.
0.3245
+67.27%